Video

Dr. Salerno Discusses Hypofractionation for Early Breast Cancer

Kilian Salerno, MD, director of Breast Radiation and Soft Tissue/Melanoma Radiation, Roswell Park Cancer Institute, discusses hypofractionated radiotherapy for the treatment of patients with early-stage breast cancer.

Kilian Salerno, MD, director of Breast Radiation and Soft Tissue/Melanoma Radiation, Roswell Park Cancer Institute, discusses hypofractionated radiotherapy for the treatment of patients with early-stage breast cancer. Salerno addressed the topic of NCCN guideline updates in breast cancer at the 2016 NCCN Annual Conference.

There is compelling evidence that hypofractionation to the whole breast elicits equivalent, if not better, outcomes for women compared with the conventional regimen. Data from two large studies showed that in addition to outcomes, cosmetic outcomes were also the same, if not better, and toxicity was more tolerable for patients.

Salerno says the tweaking of the guidelines to state that hypofractionation is “preferred” is an important change. She says she hopes that it will lead to greater adoption throughout the United States.

<<<

View more from the 2016 NCCN Annual Conference

Related Videos
Ruth M. O’Regan, MD
Paolo Caimi, MD
Jennifer Scalici, MD
Steven H. Lin, MD, PhD
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Victor Moreno, MD, PhD
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec
Sheldon M. Feldman, MD
Dana Zakalik, MD